ADMA added $2.4 million of revenue in the three months ended June 30. Its inventory grew by $47.8 million. That is the basic oddity in the latest report: sales barely moved, while the balance sheet and profit engine changed scale.
Revenue rose 2.0% to $124.4 million from the comparable period a year earlier. Gross profit climbed 28.3% to $86.3 million, lifting gross margin to 69.4% from 55.1%. Operating income rose 22.5% to $52.4 million, and diluted earnings per share reached $0.16 as the diluted share count fell 7.3%.
ADMA says the margin jump came from two things: a more favorable product mix and manufacturing improvements that increased yields. The revenue line itself was less uniform. ASCENIV sales increased by $19.6 million, while BIVIGAM volume fell by $36.4 million amid competitive pressure in the standard immune globulin industry. The smaller increases came from plasma collection centers and intermediates.
That mix matters because it turns a low-growth three-month period into a much more profitable one without requiring a similar increase in total sales. The 10-Q also shows research and development spending rising from $1.0 million to $6.0 million, suggesting the period was not simply a case of every expense line shrinking.
Management’s explanation for the gross-profit change is direct:
"The improvement in gross margin is primarily driven by favorable product mix in 2026, along with the margin benefits of the yield enhancement manufacturing process optimizations."
ADMA Biologics, 10-Q filed August 5, 2026.
In plain English, ADMA kept more of each revenue dollar because of what it sold and how it made it. The filing does not assign the margin improvement to higher prices.
Cash generation also moved sharply, though the company reports that comparison over six months rather than three. Operating cash flow was $87.8 million, versus $1.5 million a year earlier. ADMA attributed the increase primarily to higher net income and favorable timing of collections from accounts receivable.
"Cash provided in operations for the six months ended June 30, 2026 was $87.8 million, an increase of $86.3 million from the same period of a year ago, primarily driven by growth in net income and favorable timing of cash collections from accounts receivable."
ADMA Biologics, 10-Q filed August 5, 2026.
That last clause is doing real work. Accounts receivable rose 26.0% year over year, faster than revenue, while inventory rose 25.0%. Cash still increased to $136.0 million, but the operating-cash surge includes collection timing, and the working-capital balances have not yet settled into the same calm rhythm as sales.
There is also a financing cost attached to the business’s current shape. ADMA reported six-month interest expense of $5.5 million, up from $3.8 million, driven by higher average debt under its senior secured credit facility. The company disclosed JPMorgan Chase Bank as administrative agent for that credit agreement, making the lender relationship a recurring part of the balance-sheet picture rather than a one-off footnote.
At the latest close, ADMA shares were $9.29, up 4.4% on August 5, after falling 46.9% over six months. The filing leaves two operating signals pulling in different directions: profitability and cash improved, while revenue growth remained modest and receivables and inventory expanded faster than it did. ADMA’s next quarterly report leaves one factual question on the table: what will happen to those inventory and receivables balances relative to sales?
ADMA’s 10-Q attributes the margin improvement to product mix and yield-enhancement manufacturing, while its cash-flow discussion points to net income and collection timing.